Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 601–700 of 1,005
Park, S. H., Keller, E. T., & Shiozawa, Y. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0350-8 · Cited by 48
Prelaj, A., Rebuzzi, S. E., Buzzacchino, F., Pozzi, C., Ferrara, C., Frantellizzi, V., Follacchio, G. A., Civitelli, L., Vincentis, G. D., Tomao, F., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9785 · Cited by 42
“Pain at baseline, NRS Median (range) 5 (1-10) 1-3 13 (41) 4-6 11 (34) 7-10 8 (25)”
BackgroundMethodResultInfluentialRushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., & Leung, H. Y. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0681-5 · Cited by 42
Shen, C. J., Minn, I., Hobbs, R. F., Chen, Y., Josefsson, A., Brummet, M. E., Banerjee, S. R., Brayton, C. F., Mease, R. C., Pomper, M. G., et al. (2020) · Theranostics · doi:10.7150/thno.38882 · Cited by 48
“Success with the α-particle emitter 223RaCl2 for patients with metastatic PC demonstrates the potential for systemic radiopharmaceutical therapy (RPT) to improve survival with limited toxicity [4].”
BackgroundGraff, J. N., Liang, L. W., Kim, J., & Stenzl, A. (2021) · Future Oncology · doi:10.2217/fon-2020-1008 · Cited by 43
Agarwal, N., Tangen, C. M., Hussain, M., Gupta, S., Plets, M., Lara, P. N., Harzstark, A. L., Twardowski, P. W., Paller, C. J., Zylla, D. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02517 · Cited by 47
Self-citationRozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ploussard, G., Mathiéu, R., Brureau, L., et al. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2018.08.011 · Cited by 47
RetractedSen, I. B., Thakral, P., Tiwari, P., Pant, V., Das, S. S., Manda, D., & Raina, V. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01617-4 · Cited by 43
Chen, C., Wang, S., Wang, N., Zheng, Y., Zhou, J., Hong, M., Chen, Z., Wang, S., Wang, Z., & Wang, S. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155076 · Cited by 49
Yu, G., Corn, P. G., Mak, C. S. L., Liang, X., Zhang, M., Troncoso, P., Song, J. H., Lin, S.-C., Song, X., Liu, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402903121 · Cited by 54
“Ra223 is approved for treating PCa patients with bone metastasis based on improvement in overall survival (22).”
BackgroundThe contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 81
Self-citationShirley, M., & McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-014-0198-4 · Cited by 48
Mikah, P., Krabbe, L., Eminağa, O., Herrmann, E., Papavassilis, P. M., Hinkelammert, R., Semjonow, A., Schrader, A.-J., & Boegemann, M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2260-y · Cited by 45
DNA damage in leukocytes after internal ex-vivo irradiation of blood with the α-emitter Ra-223
Schumann, S., Eberlein, U., Muhtadi, R., Laßmann, M., & Scherthan, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-20364-7 · Cited by 41
Radium-223 as an Approved Modality for Treatment of Bone Metastases
Brito, A. E., & Etchebehere, E. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.11.005 · Cited by 44
Real-World Outcomes of Radium-223 Dichloride for Metastatic Castration Resistant Prostate Cancer
Kuppen, M. C. P., Westgeest, H. M., van der Doelen, M. J., van den Eertwegh, A. J. M., Coenen, J. L. L. M., Aben, K. K. H., van den Bergh, A. C., Bergman, A. M., van den Bosch, J., Celik, F., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0039 · Cited by 42
Kim, T. J., Lee, Y. H., & Koo, K. C. (2021) · Biomolecules · doi:10.3390/biom11040492 · Cited by 45
Sgouros, G. (2018) · Health Physics · doi:10.1097/hp.0000000000001000 · Cited by 52
Emerging Biomarker-Guided Therapies in Prostate Cancer
Deluce, J. E., Cardenas, L. M., Lalani, A. A., Vareki, S. M., & Fernandes, R. (2022) · Current Oncology · doi:10.3390/curroncol29070400 · Cited by 51
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
Gulley, J. L., Mulders, P., Albers, P., Banchereau, J., Bolla, M., Pantel, K., & Powles, T. B. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1107698 · Cited by 42
Plichta, K. A., Graves, S. A., & Buatti, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212095 · Cited by 45
“Other theranostic agents currently in use include 177Lu-DOTATATE (paired with Gallium-68-DOTATATE or DOTATOC PET/CT imaging) for the treatment of metastatic neuroendocrine tumors [5]; Radium-223-dichloride (paired with 99mTc-methylene diphosphonate bone scans or 18FNaF PET/CT scans) for the treatment of metastatic, ca…”
BackgroundOosting, S. F., Barriuso, J., Bottomley, A., Galotti, M., Gyawali, B., Kiesewetter, B., Latino, N. J., Martinelli, F., Pe, M. L., Pentheroudakis, G., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.004 · Cited by 41
Higano, C. S., George, D. J., Shore, N. D., Sartor, O. A., Miller, K., Conti, P. S., Sternberg, C. N., Fred Saad, C., Sade, J. P., Joaquim Bellmunt, B., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101993 · Cited by 40
Self-citationNelson, B. J. B., Wilson, J., Andersson, J. D., & Wuest, F. R. (2023) · Pharmaceuticals · doi:10.3390/ph16111622 · Cited by 44
“…spectrum It works as a calcium-mimetic by accumulating in and irradiating osteoblastic lesions, while sparing most surrounding healthy tissue [81]. that enables SPECT imaging using a low or high-energy collimator; its ability to rapidly and stably radiolabel targeting vectors under mild…”
BackgroundInfluentialBone-targeting agents in prostate cancer
Suzman, D. L., Boikos, S. A., & Carducci, M. A. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9480-2 · Cited by 53
Pacilio, M., Ventroni, G., Cassano, B., Ialongo, P., Lorenzon, L., Castro, E. D., Recine, F., Sternberg, C. N., & Mango, L. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-1044-9 · Cited by 39
de Morrée, E. S., Vogelzang, N. J., Petrylak, D. P., Budnik, N., Wiechno, P., Sternberg, C. N., Doner, K., Joaquim Bellmunt, B., Burke, J. M., de Olza, M. O., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3000 · Cited by 45
Self-citationUltrahigh resolution radiation imaging system using an optical fiber structure scintillator plate
Yamamoto, S., Kamada, K., & Yoshikawa, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21500-z · Cited by 40
Systemic treatment for metastatic prostate cancer
Gravis, G. (2019) · Asian journal of urology · doi:10.1016/j.ajur.2019.02.002 · Cited by 48
“compared six cycles of radium-223 to placebo in 921 patients with CRPC and symptomatic bone metastases without lymph node and/or visceral metastases [30].”
BackgroundEmerging therapeutic targets for patients with advanced prostate cancer
Saad, F., Shore, N. D., Zhang, T., Sharma, S., Cho, H., & Jacobs, I. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.002 · Cited by 45
Call to arms: need for radiobiology in molecular radionuclide therapy
Terry, S. Y. A., Nonnekens, J., Aerts, A., Baatout, S., de Jong, M., Cornelissen, B. T., & Pouget, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04334-3 · Cited by 44
Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
Yard, B. D., Gopal, P., Bannik, K., Siemeister, G., Hagemann, U. B., & Abazeed, M. E. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0859 · Cited by 42
“137Cs 223Ra NFE2L2 del (16-34) KEAP1 E258*”
Harsini, S., Saprunoff, H., Alden, T., Mohammadi, B., Wilson, D. C., & Bénard, F. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.246983 · Cited by 41
“Other therapeutic agents approved for the treatment of metastatic castration-resistant PCa (cabazitaxel (3), abiraterone (4), sipuleucel-T (5), enzalutamide (6), and 223Ra (7)) can improve survival.”
BackgroundFlare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
Conteduca, V., Poti, G., Caroli, P., Russi, S., Brighi, N., Lolli, C., Schepisi, G., Romeo, A., Matteucci, F., Paganelli, G., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987654 · Cited by 44
Ballal, S., Yadav, M. P., Sahoo, R. K., Tripathi, M., Dwivedi, S. N., & Bal, C. (2021) · The Prostate · doi:10.1002/pros.24137 · Cited by 40
Bauckneht, M., Bertagna, F., Donegani, M. I., Durmo, R., Miceli, A., Biasi, V. D., Laudicella, R., Fornarini, G., Berruti, A., Baldari, S., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00391-8 · Cited by 42
“GS at diagnosis was categorized into two classes for clinical interpretation, as previously described [22], while bone scan lesions were classified in < 6, 6–20, and > 20, as previously described [23].”
MethodWhy bother with alpha particles?
King, A. P., Lin, F. I., & Escorcia, F. E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05431-y · Cited by 45
“Although naturally occurring radium was first used therapeutically over a century ago [32], (223)RaCl2 only gained FDA approval in 2013 [3, 33, 34].”
BackgroundSensory nerves: A driver of the vicious cycle in bone metastasis?
Yoneda, T., Hiasa, M., Okui, T., & Hata, K. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100387 · Cited by 46
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
Rosar, F., Neher, R., Burgard, C., Linxweiler, J., Schreckenberger, M., Hoffmann, M. A., Bartholomä, M. D., Khreish, F., & Ezziddin, S. (2022) · Cancers · doi:10.3390/cancers14071696 · Cited by 41
“as abiraterone [6] or enzalutamide [7]; therapy with PARP-inhibitors, such as olaparib [8]; and bone-seeking therapy with 223Ra [9].”
BackgroundClinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Feuerecker, B., Kratochwil, C., Ahmadzadehfar, H., Morgenstern, A., Eiber, M., Herrmann, K., & Pomykala, K. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265353 · Cited by 45
“Grade 3 and 4 thrombocytopenia was reported in 6% of patients on (223)Ra and in 2% of patients on placebo (2).”
BackgroundInfluentialJapanese clinical practice guidelines for prostate cancer 2023
Kohjimoto, Y., Uemura, H., Yoshida, M., Hinotsu, S., Takahashi, S., Takeuchi, T., Suzuki, K., Shinmoto, H., Tamada, T., Inoue, T., et al. (2024) · International Journal of Urology · doi:10.1111/iju.15545 · Cited by 54
“…search was conducted using 10 keywords (Radium 223, enzalutamide, abiraterone acetate, castration-resistant prostate cancer, bone metastasis, bone-modifying agent, fracture, osteonecrosis of the jaw, skeletal-related event, and prostate-speci fi c antigen) and 3 key papers 159 – 161 for this CQ.”
New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
Jong, J. M. V. D.-D., Verheul, H. M. W., Bloemendal, H. J., de Klerk, J. M. H., Carducci, M. A., & van den Eertwegh, A. J. M. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.01.008 · Cited by 41
Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases
Wissing, M. D., van Leeuwen, F. W. B., van der Pluijm, G., & Gelderblom, H. A. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1896 · Cited by 47
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation
de Morrée, E. S., van Soest, R. J., Aghai, A., de Ridder, C., de Bruijn, P., Moghaddam-Helmantel, I. M. G., Burger, H., Mathijssen, R. H. J., Wiemer, E. A. C., de Wit, R., et al. (2016) · The Prostate · doi:10.1002/pros.23182 · Cited by 42
Luo, J. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178490 · Cited by 43
Fan, L., Wang, X., Chi, C., Wang, Y., Cai, W., Shao, X., Xu, F., Pan, J., Zhu, Y., Shangguan, X., et al. (2017) · The Prostate · doi:10.1002/pros.23381 · Cited by 40
“had been concluded to decrease the serum PSA levels but do prolong OS compared with placebo, which questions the role of the PSA level as an estimate of patient prognosis.(6) Thus, the ability to distinguish between patients with a PSA flare and those with primary refractory disease and more accurately predict the pro…”
Gholami, Y. H., Willowson, K. P., Forwood, N. J., Harvie, R. M., Hardcastle, N., Bromley, R. M., Ryu, H.-J., Yuen, S., Howell, V. M., Kuncic, Z., et al. (2018) · EJNMMI Physics · doi:10.1186/s40658-018-0217-8 · Cited by 43
Chiong, E., Murphy, D. G., Akaza, H., Buchan, N. C., Chung, B. H., Kanesvaran, R., Khochikar, M., Letran, J. L., Lojanapiwat, B., Ng, C., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14489 · Cited by 42
Rivera-Valentin, R. K., Zhu, L., & Hughes, D. P. M. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0134-4 · Cited by 41
Sapienza, M. T., & Willegaignon, J. (2019) · Clinics · doi:10.6061/clinics/2019/e835 · Cited by 39
“randomized clinical trials, such as the use of somatostatinlutetium-177 analogs for neuroendocrine tumors (2) and radio223 for bone metastases of prostate carcinoma (3).”
BackgroundCalais, J., Czernin, J. G., Thin, P., Gartmann, J., Nguyen, K., Armstrong, W. R., Allen-Auerbach, M., Quon, A. S. W., Bahri, S., Gupta, P. K., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262543 · Cited by 43
“cycles) derives mostly from prior empiric compassionate use of (177)Lu-PSMA-617 in Germany (4–6) and prospective trials using other established molecular radionuclide therapy agents ((177)Lu-DOTATATE, (223)Ra, (90)Y-ibritumomab-tiuxetan) (1,7,8).”
BackgroundMethodRahbar, K., Essler, M., Pabst, K. M., Eiber, M. J., la Fougère, C., Prasad, V., Rassek, P., Hasa, E., Dittmann, H., Bundschuh, R. A., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264456 · Cited by 46
“(223)Ra therapy results in low myelosuppression rates, and recent preclinical data demonstrated its transient effect on the bone marrow without long-term effects (1,2).”
BackgroundSelf-citationACR Appropriateness Criteria ® Non-Spine Bone Metastases
Kim, E. Y., Chapman, T. R., Ryu, S., Chang, E. L., Galanopoulos, N., Jones, J., Kubicky, C. D., Lee, C. P., Teh, B. S., Traughber, B. J., et al. (2014) · Journal of Palliative Medicine · doi:10.1089/jpm.2014.9395 · Cited by 40
Merseburger, A. S., Hammerer, P., Rozet, F., Roumeguère, T., Caffo, O., da Silva, F. C., & Alcaraz, A. (2014) · World Journal of Urology · doi:10.1007/s00345-014-1406-2 · Cited by 42
Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041051 · Cited by 43
“Within this group of radioisotopes, radium-223 (alkaline earth metal, group 2) has been extensively studied both in vitro and in vivo, and has paved the way for the use of alpha-emitting radioelements in patients [72].”
BackgroundJalloul, W., Ghizdovăţ, V., Stolniceanu, C. R., Ionescu, T. M., Grierosu, I. C., Păvăleanu, I., Moscalu, M., & Ştefănescu, C. (2023) · Pharmaceuticals · doi:10.3390/ph16121679 · Cited by 44
“Furthermore, α -particle emitters have significant curative effects, particularly in patients with limited therapeutic options and metastatic spread [2–4].”
BackgroundAlpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy
Tosato, M., Favaretto, C., Kleynhans, J., Burgoyne, A. R., Gestin, J., van der Meulen, N. P., Jalilian, A. R., Köster, U., Asti, M., & Radchenko, V. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108990 · Cited by 44
“As a result, Ra 2 + inherently targets bone tissue, accumulating in areas of high osteoclastic activity, such as bone borders and bone metastases [5,9,225].”
Recent advances in theranostics and oncology PET: emerging radionuclides and targets
Watabe, T., Hirata, K., Iima, M., Yanagawa, M., Saida, T., Sakata, A., Ide, S., Honda, M., Kurokawa, R., Nishioka, K., et al. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02090-z · Cited by 45
“Although 223 Ra was shown to extend OS in the ALSYMPCA trial [81], its therapeutic effect—such as PSA reduction— was limited, because it does not directly target tumor cells.”
Aggarwal, R. R., Harris, A. E., Formaker, C., Small, E. J., Molina, A., Griffin, T. W., & Ryan, C. J. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.03.010 · Cited by 39
Targeting kallikrein-related peptidases in prostate cancer
Mavridis, K., Avgeris, M., & Scorilas, A. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.880693 · Cited by 39
Epigenetic therapy in urologic cancers: an update on clinical trials
Faleiro, I., Leao, R. R. N., Binnie, A., de Mello, R. A., Maia, A.-T., & Castelo‐Branco, P. (2016) · Oncotarget · doi:10.18632/oncotarget.14226 · Cited by 46
Bauckneht, M., Capitanio, S., Donegani, M. I., Zanardi, E., Miceli, A., Murialdo, R., Raffa, S., Tomasello, L., Vitti, M., Cavo, A., et al. (2019) · Cancers · doi:10.3390/cancers12010031 · Cited by 38
Overall survival and second primary malignancies in men with metastatic prostate cancer
Mehtälä, J., Zong, J., Vassilev, Z. P., Brobert, G., Gabarró, M. S., Stattin, P. E., & Khanfir, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227552 · Cited by 42
“1 years on average, which is also in line with prior studies from the same time period [6,14].”
ResultSood, A. K., Satapathy, S., Mittal, B., Das, C. K., Singh, S., Mavuduru, R. S., & Bora, G. (2020) · Indian Journal of Nuclear Medicine · doi:10.4103/ijnm.ijnm_130_20 · Cited by 40
Önal, C., Özyiğit, G., Oymak, E., Güler, O. C., Tilki, B., Hürmüz, P., & Akyol, F. H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05298-z · Cited by 37
Ahmadzadehfar, H., Matern, R., Baum, R. P., Seifert, R., Kessel, K., Bögemann, M., Kratochwil, C., Rathke, H. G., Ilhan, H., Svirydenka, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05383-3 · Cited by 44
Molecular pathology and prostate cancer therapeutics: from biology to bedside
Rodrigues, D. N., Butler, L. M., Estelles, D. L., & Bono, J. S. D. (2013) · The Journal of Pathology · doi:10.1002/path.4272 · Cited by 44
Spreafico, A., Chi, K. N., Sridhar, S. S., Smith, D. C., Carducci, M. A., Kavsak, P. A., Wong, T., Wang, L. E., Ivy, S. P., Mukherjee, S. D., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0106-5 · Cited by 41
Massard, C., Oulhen, M., Moulec, S. L., Auger, N., Foulon, S., Abou-Lovergne, A., Billiot, F., Valent, A., Marty, V., Loriot, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10396 · Cited by 40
The prostate cancer landscape in Europe: Current challenges, future opportunities
Marhold, M., Kramer, G., Krainer, M., & Magnen, C. L. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.033 · Cited by 42
Filippi, L., Urso, L., Bianconi, F., Palumbo, B., Marzola, M. C., Evangelista, L., & Schillaci, O. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2192351 · Cited by 38
“Following the results of the ALYSMPCA trial demonstrating a survival benefit in mCRPCa subjects treated with 223Ra-dichloride, in 2013 the FDA approved XofigoTM [5,6].”
BackgroundInfluentialThe current status of prostate cancer treatment and PSMA theranostics
Uemura, M., Watabe, T., Hoshi, S., Tanji, R., Yaginuma, K., & Kojima, Y. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231182293 · Cited by 41
Radiochemistry: A Hot Field with Opportunities for Cool Chemistry
Bowden, G. D., Scott, P. J. H., & Boros, E. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c01050 · Cited by 40
Francini, E., Agarwal, N., Castro, E., Cheng, H. H., Chi, K. N., Clarke, N. W., Mateo, J., Rathkopf, D. E., Fred Saad, C., & TOMBAL, B. F. (2024) · European Urology · doi:10.1016/j.eururo.2024.09.008 · Cited by 41
Mei, S., Zhang, H., Hirz, T., Jeffries, N. E., Xu, Y., Baryawno, N., Wu, S., Wu, C., Patnaik, A., Saylor, P. J., et al. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0791 · Cited by 49
Progress in the Treatment of Advanced Prostate Cancer
Sternberg, C. N., Petrylak, D. P., Madan, R. A., & Parker, C. C. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.117 · Cited by 41
Self-citationAndrogen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer
Izumi, K., Li, L., & Chang, C. (2014) · Clinical Investigation · doi:10.4155/cli.14.77 · Cited by 41
Corticosteroids in the Management of Prostate Cancer: A Critical Review
Ndibe, C., Wang, C. G., & Sonpavde, G. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0320-6 · Cited by 42
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Dragomir, A., Dinea, D., Vanhuyse, M., Cury, F., & Aprikian, A. G. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-252 · Cited by 41
Etchebehere, E., Araujo, J. C., Milton, D. R., Erwin, W. D., Wendt, R. E., Swanston, N. M., Fox, P. S., Macapinlac, H. A., & ROHREN, E. M. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001118 · Cited by 38
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
Heinrich, D. A., Bektić, J., Bergman, A. M., Caffo, O., Cathomas, R. L., Chi, K. N., Daugaard, G., Keizman, D., Kindblom, J., Kramer, G., et al. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.08.020 · Cited by 38
“Median overall survival (co-primary endpoint)was longer (14.9 vs. 11.3 months; hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.58- 0.83; P< .001) in patients receiving radium-223 and BSoC compared with those receiving placebo with BSoC.6 Time to first SSE (secondary endpoint)was longer in the radium-223 arm (…”
BackgroundMethodResultInfluentialSelf-citationStereotactic Body Radiation Therapy for Spinal Malignancies
Osborn, V. W., Lee, A., & Yamada, Y. J. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818802304 · Cited by 39
Saad, F., Gillessen, S., Heinrich, D. A., Keizman, D., O’Sullivan, J. M., Nilsson, S. F., Miller, K., Wirth, M. P., Reeves, J. A., Seger, M. A., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.012 · Cited by 42
Self-citationAbouzayed, A., Yim, C., Mitran, B., Rinne, S. S., Максимилианович, Т. В., Larhed, M., Rosenström, U., & Orlova, A. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070358 · Cited by 35
“Therefore, new approaches need to be investigated to further improve the detection and management of prostate cancer patients [4,5].”
BackgroundWickstroem, K., Karlsson, J., Ellingsen, C., Cruciani, V., Kristian, A., Hagemann, U. B., Bjerke, R. M., Ryan, O. B., Lindén, L., Mumberg, D., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12040155 · Cited by 40
“clinical trial demonstrated an overall survival benefit in patients with symptomatic bone metastases and no known visceral metastases [3].”
BackgroundUkon, N., Zhao, S., Washiyama, K., Oriuchi, N., Tan, C., Shimoyama, S., Aoki, M., Kubo, H., Takahashi, K., & Ito, H. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00326-7 · Cited by 38
Noguchi, M., Fujimoto, K., Arai, G., Uemura, H., Hashine, K., Matsumoto, H., Fukasawa, S., Kohjimoto, Y., Nakatsu, H., Takenaka, A., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7847 · Cited by 44
The Role of Theranostics in Prostate Cancer
O’Dwyer, E., Bodei, L., & Morris, M. J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.004 · Cited by 45
Agarwal, N., Azad, A., Carles, J., Chowdhury, S., McGregor, B. A., Merseburger, A. S., Oudard, S. M., Saad, F., Soares, A., Benzaghou, F., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1096 · Cited by 40
Biological and Clinical Aspects of Metastatic Spinal Tumors
Litak, J., Czyżewski, W., Szymoniuk, M., Sakwa, L., Pasierb, B., Litak, J., Hoffman, Z., Kamieniak, P., & Roliński, J. (2022) · Cancers · doi:10.3390/cancers14194599 · Cited by 43
Metastatic Castration-Resistant Prostate Cancer: Time for Innovation
Tucci, M., Scagliotti, G. V., & Vignani, F. (2015) · Future Oncology · doi:10.2217/fon.14.145 · Cited by 39
Challenges of managing elderly men with prostate cancer
Jha, G. G., Anand, V., Soubra, A., & Konety, B. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.71 · Cited by 47
Kind, F., Michalski, K., Yousefzadeh‐Nowshahr, E., Meyer, P. T., Mix, M. D., & Ruf, J. (2022) · EJNMMI Research · doi:10.1186/s13550-022-00891-1 · Cited by 38
“This assumption is supported by data on haematological side effects in the control arm of the phase III ALSYMPCA-trial assessing [223Ra]Radiumdichloridetreatment of progressive castration-resistant prostate cancer with two or more bone metastases [13].”
ResultInfluentialSelçuk, N. A., Beydağı, G., Demirci, E., Ocak, M., Çelik, S., Öven, B. B., Toklu, T., Karaaslan, İ. Ş., Akçay, K., Sönmez, Ö., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265546 · Cited by 39
“Current standard treatment options for mCRPC include taxane-based chemotherapy (docetaxel and cabazitaxel) (2,3), novel androgen axis drug treatment (abiraterone or enzalutamide) (4,5), and bone-seeking [(223)Ra]RaCl2 therapy (6), which are approved by the European Medicines Agency and the U.”
BackgroundUnlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers
Cao, P. H. A., Dominic, A., Lujan, F. E., Senthilkumar, S., Bhattacharya, P. K., Frigo, D. E., & Subramani, E. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00869-9 · Cited by 44
“Radium-223 is an intravenously injected salt that mimics calcium, binding to hydroxyapatite and assimilating into bone areas where active mineralization occurs 205,206 .”
Vaishampayan, U. N., Shevrin, D. H., Stein, M. N., Heilbrun, L. K., Land, S. J., Stark, K., Li, J., Dickow, B., Heath, E. I., Smith, D. W., et al. (2015) · Urology · doi:10.1016/j.urology.2015.08.008 · Cited by 37
Afshar, M., Evison, F., James, N. D., & Patel, P. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.003 · Cited by 40
Self-citationLiu, L., Cui, L., Zhang, X., Cao, J., Chang, N., Tang, X., Qi, S., Zhang, X., Yin, H. J., & Zhang, J. (2015) · Medicine · doi:10.1097/md.0000000000001998 · Cited by 45
McNeel, D. G., Bander, N. H., Beer, T. M., Drake, C. G., Fong, L. H., Harrelson, S. S., Kantoff, P. W., Madan, R. A., Oh, W. K., Peace, D. J., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0198-x · Cited by 39
Self-citationImproved survival for patients with de novo metastatic prostate cancer in the last 20 years
Berg, K. D., Thomsen, F. B., Mikkelsen, M. K., Ingimarsdóttir, I. J., Hansen, R. B., Kejs, A. M. T., & Brasso, K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.025 · Cited by 37
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.